Mechanistically, this was achieved through an enhancement in the expression of MHC class II proteins on intratumoral myeloid cells, increasing access by CD4+ tumor-infiltrating T cells, and decreasing the percentage of intratumoral T cells that express inhibitory immune checkpoint molecules. Here, CD4 is linked to neoplasm.